Related Experiment Videos
Pitfalls in lung cancer molecular pathology: how to limit them in routine practice?
1Laboratory of Clinical and Experimental Pathology, Louis Pasteur Hospital, Nice, France.
Abstract:
New treatment options in advanced non-small cell lung carcinoma (NSCLC) targeting activating epidermal growth factor receptor (EGFR) gene mutations and other genetic alterations demonstrated the clinical significance of the molecular features of specific subsets of tumors. Therefore, the development of personalized medicine has stimulated the routine integration into pathology departments of somatic mutation testing. However, clinical mutation testing must be optimized and standardized with regard to histological profile, type of samples, pre-analytical steps, methodology and result reporting. Routine molecular testing in NSCLC is currently moving beyond EGFR mutational analysis. Recent progress of targeted therapies will require molecular testing for a wide panel of mutations for a personalized molecular diagnosis. As a consequence, efficient testing of multiple molecular abnormalities is an urgent requirement in thoracic oncology. Moreover, increasingly limited tumor sample becomes a major challenge for molecular pathology. Continuous efforts should be made for safe, effective and specific molecular analyses. This must be based on close collaboration between the departments involved in the management of lung cancer. In this review we explored the practical issues and pitfalls surrounding the routine implementation of molecular testing in NSCLC in a pathology laboratory.
Insights
Personalized medicine in advanced non-small cell lung carcinoma (NSCLC) requires standardized somatic mutation testing. Optimizing molecular diagnostics is crucial for effective targeted therapies and personalized diagnosis, despite challenges like limited tumor samples.
Area of Science:
- Oncology
- Pathology
- Molecular Diagnostics
Background:
- Targeted therapies for non-small cell lung carcinoma (NSCLC) have highlighted the clinical importance of molecular features, driving personalized medicine.
- Somatic mutation testing is increasingly integrated into pathology departments for advanced NSCLC treatment selection.
Purpose of the Study:
- To review the practical challenges and pitfalls in the routine implementation of molecular testing in NSCLC pathology laboratories.
- To emphasize the need for optimization and standardization of mutation testing methodologies for personalized molecular diagnosis.
Main Methods:
- Review of current practices and challenges in molecular testing for NSCLC.
- Discussion on the requirements for histological profile, sample types, pre-analytical steps, methodology, and reporting.
- Exploration of the need for broad molecular profiling beyond epidermal growth factor receptor (EGFR) mutations.
Main Results:
- Routine molecular testing in NSCLC is expanding beyond EGFR analysis to accommodate a wider range of targeted therapies.
- Limited tumor sample availability presents a significant challenge for comprehensive molecular pathology.
- Standardization and optimization of testing are essential for accurate and efficient molecular diagnosis.
Conclusions:
- Efficient, safe, and specific molecular analyses are urgently required for personalized diagnosis in thoracic oncology.
- Close collaboration between departments involved in lung cancer management is vital for successful implementation of molecular testing.
- Addressing practical issues is key to advancing personalized medicine in NSCLC.